Lower LDL-C targets (e.g., <70 mg/dL high-risk, <55 mg/dL very-high-risk/post-event) reduce cardiovascular events
Summary
The 'lower is better' relationship between LDL-C and ASCVD risk is supported by RCTs of statins, ezetimibe (IMPROVE-IT), and PCSK9 inhibitors (FOURIER, ODYSSEY OUTCOMES), as well as Mendelian randomization. The specific numeric targets in the post (<70, <60, <55 mg/dL) map closely to ESC/EAS 2019 guideline thresholds: <100 for moderate risk, <70 for high risk, <55 for very high risk / post-event, with a <40 option for recurrent events. ACC/AHA 2018 uses a threshold-trigger approach (LDL ≥70 mg/dL in very-high-risk secondary prevention triggers intensification) rather than explicit targets, but arrives at similar practical thresholds. Benefit per mmol/L LDL reduction is consistent across baseline levels down to very low LDL, with no clear lower bound of safety observed.
Five-score assessment
Scope
- Low-risk primary prevention adults without elevated ASCVD risk
- Specific numeric thresholds in children or pregnancy
- Populations where guidelines use percent-reduction rather than absolute targets (e.g., 2018 ACC/AHA primary prevention)
Evidence sources
Supporting (6)
-
Endorses LDL-C goals of <100 (moderate risk), <70 (high risk), <55 (very-high risk), and <40 mg/dL (recurrent events within 2 years).
-
Recommends intensifying therapy when LDL-C ≥70 mg/dL in very-high-risk secondary-prevention patients, aligning with a <70 mg/dL functional threshold.
-
Each 1 mmol/L (~39 mg/dL) LDL-C reduction lowers major vascular events ~22%, with proportional benefit preserved at low baseline LDL-C.
-
Adding ezetimibe to statin lowered LDL-C to ~54 mg/dL and further reduced CV events post-ACS, supporting sub-70 targets.
-
Evolocumab reduced LDL-C to median ~30 mg/dL and cut CV events in established ASCVD, supporting very-low LDL targets.
-
Alirocumab post-ACS reduced MACE with benefit greatest in patients with baseline LDL ≥100 mg/dL, reinforcing aggressive post-event lowering.